Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.

In a phase I trial the toxicity and immunomodulatory effects of combined treatment with intravenous (i.v.) bispecific monoclonal antibody BIS-1 and subcutaneous (s.c.) interleukin 2 (IL-2) was studied in renal cell cancer patients. BIS-1 combines a specificity against CD3 on T lymphocytes with a spe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kroesen, B. J., Buter, J., Sleijfer, D. T., Janssen, R. A., van der Graaf, W. T., The, T. H., de Leij, L., Mulder, N. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033411/
https://www.ncbi.nlm.nih.gov/pubmed/7917912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033411/
https://www.ncbi.nlm.nih.gov/pubmed/7917912

Ejemplares similares